POEM

orange__line

A Phase IIa Pharmacokinetic-pharmacodynamic Study to Confirm the Inhibitory Effect of Temsirolimus, Targeting the mTOR Pathway in Endometrial Carcinoma

Type of Application: Clinical trial of new indication.

Experimental drug: The study dose of temsirolimus will be 25 mg administered intravenously, infused over a 30- to 60-minute period once weekly for 28 days (Total doses: 4 doses). Temsirolimus is a selective inhibitor of mTOR (mammalian target of rapamycin). Pharmacotherapeutic group: Protein Kinase Inhibitors; ATC code: L01X E09.

NAME TUMOR TYPE TITLE PHASE N SITES COUNTRY STATUS
POEM Endometrial A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus IIa 10 3 Spain Accrual finalized

Botón CONTACT US